Vancomycin in Meningitis Treatment: Role and Rationale

Indications for Adding Vancomycin

The Infectious Diseases Society of America recommends adding vancomycin to third-generation cephalosporin therapy when there is suspicion of penicillin-resistant pneumococci, particularly in patients who have recently traveled to areas with high resistance rates 1, 2
Vancomycin is indicated when pneumococcal resistance to both penicillin and cephalosporins is documented or suspected, with a recommended regimen of ceftriaxone 2g IV every 12 hours plus vancomycin 15-20 mg/kg IV every 12 hours plus rifampicin 600 mg orally/IV every 12 hours 1, 3, 2

The American Academy of Neurology notes that CSF penetration of vancomycin is poor, approximately 1% with uninflamed meninges and only 5% with inflamed meninges, with maximum CSF concentrations of 2-6 μg/mL 4, 5
Due to poor CSF penetration, vancomycin is typically combined with a third-generation cephalosporin rather than used as monotherapy for meningitis, with some experts recommending adding rifampicin to vancomycin for CNS infections because rifampicin achieves bactericidal concentrations in CSF (22% penetration) 4, 5

The Centers for Disease Control and Prevention recommend that for empiric treatment of suspected bacterial meningitis, a third-generation cephalosporin (ceftriaxone 2g IV every 12 hours or cefotaxime 2g IV every 6 hours) is the foundation of therapy, with vancomycin (15-20 mg/kg IV every 12 hours) added if penicillin-resistant pneumococci are suspected 1, 2, 6
For confirmed pneumococcal meningitis with penicillin or cephalosporin resistance, treatment should be continued for 14 days 1, 2

The European Society of Clinical Microbiology and Infectious Diseases notes that vancomycin should not be used as monotherapy for meningitis due to poor CSF penetration and documented treatment failures, and high-dose, continuous infusion of vancomycin may be considered in patients not responding to standard dosing to improve CSF penetration 4, 5

The American College of Physicians recommends vancomycin for pneumococcal strains with reduced susceptibility to penicillin or cephalosporins, with a minimum inhibitory concentration (MIC) of >0.06 mg/L for penicillin and >0.5 mg/L for cephalosporins, in patients with meningitis 7, 8
Vancomycin provides coverage for pneumococci resistant to both penicillin and third-generation cephalosporins, requiring combination therapy with ceftriaxone or cefotaxime, in patients with meningitis 7, 8
The Infectious Diseases Society of America recommends adding vancomycin empirically if the patient has recently traveled to regions with high pneumococcal resistance rates, in patients with suspected meningitis 7
Vancomycin is the recommended agent for methicillin-resistant Staphylococcus aureus (MRSA) meningitis, according to the Clinical Microbiology and Infection guidelines 9
The treatment duration for staphylococcal meningitis should be at least 14 days, as recommended by the Clinical Microbiology and Infection guidelines 9

The Journal of Infection recommends adding vancomycin to third-generation cephalosporin therapy in scenarios such as recent travel to areas with high pneumococcal resistance rates, known local prevalence of penicillin-resistant pneumococci, suspected or confirmed MRSA infection, and immunocompromised patients at higher risk for resistant organisms, in patients with suspected meningitis 7, 8
Vancomycin should be dosed at 15-20 mg/kg IV every 12 hours, targeting serum trough concentrations of 15-20 μg/mL, as recommended by the Journal of Infection guidelines 7, 8

The Journal of Infection recommends monitoring vancomycin trough levels to ensure therapeutic concentrations (15-20 μg/mL), in patients with meningitis 8

The Infectious Diseases Society of America recommends vancomycin as the treatment of choice for methicillin-resistant S. aureus (MRSA) meningitis, but it should be administered in high doses (15-20 mg/kg every 8-12 hours) with strict monitoring of serum levels, aiming for 15-20 μg/mL, and considering linezolid as a superior alternative, especially when the vancomycin minimum inhibitory concentration (MIC) is ≥2 mg/L 10

Vancomycin should never be used as monotherapy due to its poor penetration into the cerebrospinal fluid (CSF), with a penetration of only 1% in non-inflamed meninges and 5% in inflamed meninges, resulting in maximum CSF concentrations of only 2-6 μg/mL 11

For confirmed or suspected MRSA, the American College of Physicians recommends a combination therapy of vancomycin 15-20 mg/kg IV every 8-12 hours (maximum 2g per dose) and rifampicin 600 mg IV/oral every 12 hours, with strict monitoring of serum levels and adjustment of doses to maintain 15-20 μg/mL 10
The Infectious Diseases Society of America recommends that for S. aureus sensitive to methicillin (MSSA), a beta-lactam antibiotic is superior to vancomycin, with cloxacillin or oxacillin as first-line options 10

Recent evidence favors linezolid over vancomycin for S. aureus meningitis, especially when the vancomycin MIC is ≥2 mg/L, with a comparative study showing microbiological superiority of linezolid (78% vs 25% clearance of CSF at day 5, p=0.044) 10

The Infectious Diseases Society of America recommends a minimum of 14 days of treatment for staphylococcal meningitis, with extension based on clinical and microbiological response, and consideration of a control lumbar puncture at 48-72 hours in cases of documented resistance 11

Concomitant infective endocarditis is the most important independent risk factor for mortality, with an odds ratio of 21.00 (95% CI: 1.834-240.515, p=0.01) 10